HOME >> BIOLOGY >> NEWS
JCI Table of Contents, November 3, 2003

R> Phone: 215-573-2955
Fax: 215-573-7599
E-mail: tlaufer@mail.med.upenn.edu

View the PDF of this article at: https://www.the-jci.org/press/18310.pdf

**********************************************

ARNT mice controlling skin function?

Junji Takeda and colleagues from Osaka University and the National Cancer Institute reveal that the aryl hydrocarbon receptor nuclear translocator (ARNT) affects the structure of ceramides in the skin and disrupts the function of the epidermal barrier, which protects against foreign environmental stimuli and injury. These findings are reported in the November 3 issue of the Journal of Clinical Investigation.

ARNT, a transcription factor of the Per/AHR/ARNT/Sim family, regulates gene expression in response to environmental stimuli such as xenobiotics and hypoxia. To examine its role in the epidermis, Takeda and colleagues disrupted Arnt in keratinocytes. While the architecture of the stratum corneum in Arnt/ mice was found to be similar to that in control mice, the permeability barrier function and the composition of ceramides were significantly different. In particular, 4-desaturated and 4-hydroxylated ceramide species were diminished in the Arnt/ mice, whereas 4-saturated ceramides were elevated.

These data suggest that ARNT regulates ceramide biosynthesis through 4-desaturation and that maintenance of ceramide composition is important in epithelial barrier function.

TITLE: Alteration of the 4-sphingenine scaffolds of ceramides in keratinocyte-specific Arnt-deficient mice affects skin barrier function

AUTHOR CONTACT:
Junji Takeda
Osaka University Graduate School of Medicine, Osaka, Japan.
Phone: 81-6-6879-3262
Fax: 81-6-6879-3266
E-mail: takeda@mr-en
'"/>


Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
3-Nov-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, 1 October, 2003
4. JCI Table of Contents, September 15, 2003
5. JCI Table of Contents
6. JCI Table of Contents, 15 August 2003
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
Cached News: